Thank you all for having me. It's my pleasure to speak to the UK Myeloma Autumn Research Day.

I'm going to be talking about what questions are current myeloma trials not answering.

I'm Dr. Vinay Prasad. I'm a professor here at the University of California, San Francisco.

I'm a practicing hemank doc, and I take care of myeloma in addition to all other malignancies.

So let's get started.

I think we have to always remember when we talk about multiple myeloma that patients care

about two things and only two things.

They care about living longer, their duration of survival, their overall survival, and

they care about living better. And living better

is best ascertained with health-related quality of life that actually measures someone's

entire cancer journey that doesn't just measure the first six months on treatment or the first

12 months that measures the entire cancer journey. It's a cumulative experience. Those are the

only two things patients care

about. Everything else is something that doctors care about that we invented, that

sometimes correlate with these things, but not always. So let's talk about that. Doctors

care about. We talk a lot about depth of response. For us, it makes a big difference

if someone's in VGPR versus CR.

We talk about minimal residual disease.

This is to this date still a prognostic marker, i.e.

if you attain lower rates of minimal residual disease, you will have better PFS and better OS.

It's prognostic.

But it is not yet proven to be a surrogate,

...